

13. Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007–2008 and 2008–2009 influenza seasons. *Clin Infect Dis*. 2009;49(12):1828–35.
14. Kawai N, Ikematsu H, Tanaka O, Matsuura S, Maeda T, Yamauchi S, et al. Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007–2008 and 2008–2009 seasons. *J Infect Chemother*. 2011; 17(3):375–81.
15. Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami C, Kawaoka Y, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. *Clin Infect Dis*. 2008;47(3):339–45.
16. Saito R, Sato I, Suzuki Y, Baranovich T, Matsuda R, Ishitani N, et al. Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation. *Pediatr Infect Dis J*. 2010;29(10):898–904.
17. Ishizuka H, Yoshida S, Okabe H, Yoshihara K. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. *J Clin Pharmacol*. 2010;50(11):1319–29.
18. Baranovich T, Saito R, Suzuki Y, Zaraket H, Dapat C, Caperig-Dapat I, et al. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008–2009 season. *J Clin Virol*. 2010;47(1):23–8.
19. Zaraket H, Kondo H, Tabet C, Hanna-Wakim R, Suzuki Y, Dbaibo GS, et al. Genetic diversity and antiviral drug resistance of pandemic H1N1 2009 in Lebanon. *J Clin Virol*. 2011;51(3): 170–4.
20. Ujike M, Ejima M, Anraku A, Shimabukuro K, Obuchi M, Kishida N, et al. Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009–2010. *Emerg Infect Dis*. 2011;17(3):470–9.
21. Renaud C, Kuypers J, Englund JA. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. *J Clin Virol*. 2011;52(2):70–8.
22. Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. *BMC Infect Dis*. 2011;11:134.

# Reducing Occurrence and Severity of Pneumonia Due to Pandemic H1N1 2009 by Early Oseltamivir Administration: A Retrospective Study in Mexico

Anjarath Lorena Higuera Iglesias<sup>1</sup>, Koichiro Kudo<sup>2\*</sup>, Toshie Manabe<sup>2</sup>, Alexander Enrique Corcho Berdugo<sup>1</sup>, Ariel Corrales Baeza<sup>1</sup>, Leticia Alfaro Ramos<sup>1</sup>, René Guevara Gutiérrez<sup>1</sup>, María Eugenia Manjarrez Zavala<sup>1</sup>, Jin Takasaki<sup>2</sup>, Shinyu Izumi<sup>2</sup>, Edgar Bautista<sup>1</sup>, José Rogelio Perez Padilla<sup>1</sup>

<sup>1</sup> National Institute for Respiratory Disease, Mexico City, Mexico, <sup>2</sup> National Center for Global Health and Medicine, Tokyo, Japan

## Abstract

**Background:** Anti-viral treatment has been used to treat severe or progressive illness due to pandemic H1N1 2009. A main cause of severe illness in pandemic H1N1 2009 is viral pneumonia; however, it is unclear how effective antiviral treatment is against pneumonia when administered >48 hours after symptom onset. Therefore, we aimed to determine how time from symptom onset to antiviral administration affected the effectiveness of antiviral treatment against pneumonia due to pandemic (H1N1) 2009.

**Methods/Principal Findings:** A retrospective medical chart review of 442 patients was conducted in a hospital in Mexico. Subjects had tested positive for pandemic H1N1 2009 virus by real-time reverse-transcriptase-polymerase-chain-reaction and were administered oseltamivir. Median time from symptom onset to oseltamivir administration was 5.0 days (range, 0–43). 442 subjects, 71 (16.1%) had severe pneumonia which required mechanical ventilation, 191 (43.2%) had mild to moderate pneumonia, and 180 (40%) did not have pneumonia. Subjects were divided into four groups based on time to oseltamivir administration: ≤2, 3–7, 8–14, and >14 days. Severity of respiratory features was associated with time to treatment, and multivariate analysis indicated that time to oseltamivir administration was associated with severity of respiratory features. A proportional odds model indicated that 50% probability for occurrence of pneumonia of any severity and that of severe pneumonia in patients who would develop pneumonia reached at approximately 3.4 and 21 days, respectively, after symptom onset. Patients with a shorter time to oseltamivir administration were discharged earlier from the hospital.

**Conclusions:** Earlier initiation of oseltamivir administration after symptom onset significantly reduced occurrence and severity of pneumonia and shortened hospitalization due to pandemic H1N1 2009. Even when administered >48 hours after symptom onset, oseltamivir showed considerable potential for reducing pneumonia. Application of these results would benefit patients affected by future influenza pandemics.

**Citation:** Higuera Iglesias AL, Kudo K, Manabe T, Corcho Berdugo AE, Baeza AC, et al. (2011) Reducing Occurrence and Severity of Pneumonia Due to Pandemic H1N1 2009 by Early Oseltamivir Administration: A Retrospective Study in Mexico. PLoS ONE 6(7): e21838. doi:10.1371/journal.pone.0021838

**Editor:** Malcolm Gracie Semple, University of Liverpool, United Kingdom

**Received:** January 18, 2011; **Accepted:** June 13, 2011; **Published:** July 8, 2011

**Copyright:** © 2011 Higuera Iglesias et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by the Japan Initiative for Global Research Network on Infectious Diseases from the Ministry of Education, Culture, Sports, Science and Technology of Japan at <http://www.crnid.riken.jp/pfrc/indexE.html>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: [kudo@dcc.go.jp](mailto:kudo@dcc.go.jp)

## Introduction

Pandemic H1N1 2009 emerged in Mexico in March 2009 [1] and rapidly spread throughout the world. The fatality rate and the frequency of severe cases varied among countries and regions even among different regions within the same country [2,3]. Mexico reported a number of cases with severe clinical presentations and deaths, especially in the early period of the outbreak. This occurred at least in part because the novelty of the influenza strain was not recognized until April 23, 2009 [1,4]. The World Health Organization [5] and the Center for Disease Control and Prevention [6] recommended early initiation of treatment with antiviral drugs in patients with pandemic H1N1 2009 virus infection with severe or progressive illness as well as in high-risk

populations. The main cause of severe illness in pandemic H1N1 2009 was viral pneumonia [1,3,7,8,9] which is relatively rare in seasonal influenza. Oseltamivir has been used to treat influenza virus infection. The efficacy of oseltamivir treatment commencing >48 h after symptom onset in seasonal influenza has not been established [10]. There has been concern whether the time-interval from symptom onset to administration of oseltamivir affects clinical features on patients with pandemic H1N1 2009 virus infection. This study investigated how the post-onset window to oseltamivir administration affected the occurrence and severity of pneumonia and the duration of hospitalization in patients treated at the National Institute of Respiratory Diseases (INER) in Mexico City, Mexico during the pandemic period.

**Table 1.** Characteristics of study patients.

Variable	Oseltamivir administration				Total	P value
	Group 1 ≤2	Group 2 3–7	Group 3 8–14	Group 4 >14		
<b>Days from symptom onset until oseltamivir administration</b>						
<b>No. of patients (% of all study patients)</b>	<b>n=92 (20.8%)</b>	<b>n=213 (48.2%)</b>	<b>n=101 (22.9%)</b>	<b>n=36 (8.1%)</b>	<b>n=422 (100%)</b>	
<b>Hospitalized/ambulatory, No. (% in each group)</b>						0.000 <sup>2</sup>
Hospitalized	21 (22.8)	107 (50.2)	79 (78.2)	34 (94.4)	241 (54.5)	
Ambulatory	71 (77.2)	106 (49.8)	22 (21.8)	2 (5.6)	201 (45.5)	
<b>Deaths, No. (% in each group)</b>						0.004 <sup>4</sup>
	1 (1.1)	10 (4.7)	9 (8.9)	4 (11.1)	24 (5.7)	
<b>Age (y), mean ± SD</b>	31.4±16	32.8±16.4	37.8±16.2	38.5±17.4	34±16.5	0.010 <sup>1</sup>
Range	1.3–73.5	0.4–74.6	0.7–81.4	0.7–81.4	0–85	
<b>Age (y), No. (% in each group)</b>						
<1	0 (0.0)	5 (2.3)	2 (2.0)	1 (2.8)	8 (1.8)	
1 – <5	5 (5.4)	14 (6.6)	4 (4.0)	2 (5.6)	25 (5.7)	
5 – <10	4 (4.3)	5 (2.3)	2 (2.0)	0 (0.0)	11 (2.5)	
10 – <18	10 (10.9)	16 (7.5)	4 (4.0)	1 (2.8)	31 (7.0)	
18 – <50	60 (65.2)	141 (66.2)	67 (66.3)	24 (66.7)	292 (66.1)	
50 – <65	12 (13.0)	29 (13.6)	20 (19.8)	6 (16.7)	67 (15.2)	
≥65	1 (1.1)	3 (1.4)	2 (2.0)	2 (5.6)	8 (1.8)	
<b>Male sex, No. (% in each group)</b>	55 (59.8)	114 (53.5)	56 (55.4)	24 (66.7)	249 (56.3)	0.436 <sup>2</sup>
<b>Socioeconomic background<sup>†</sup>, No. (% in each group)</b>						0.001 <sup>3</sup>
0	5 (5.4)	12 (5.6)	19 (18.8)	6 (16.7)	42 (9.5)	
1	7 (7.6)	29 (13.6)	14 (13.9)	11 (30.6)	61 (13.8)	
2	75 (81.5)	146 (68.5)	61 (60.4)	14 (38.9)	296 (67.0)	
3	4 (4.3)	18 (8.5)	4 (4.0)	4 (11.1)	30 (6.8)	
4	0 (0.0)	4 (1.9)	3 (3.0)	1 (2.8)	8 (1.8)	
5	1 (1.1)	4 (1.9)	0 (0.0)	0 (0.0)	5 (1.1)	
<b>Influenza vaccination in 2008 and/or 2009, No. (% in each group)</b>	3 (3.3)	4 (1.9)	4 (4.0)	0 (0.0)	11 (2.5)	0.499 <sup>2</sup>
<b>Comorbidities and others, No. (% in each group)</b>						
Obesity	7 (7.6)	28 (13.1)	15 (14.9)	4 (11.1)	54 (12.2)	0.442 <sup>2</sup>
Diabetes	2 (2.2)	13 (6.1)	8 (7.9)	2 (5.6)	25 (5.7)	0.370 <sup>2</sup>
Hypertension	5 (5.4)	17 (8.0)	11 (10.9)	5 (13.9)	38 (8.6)	0.357 <sup>2</sup>
Chronic heart failure	0 (0.0)	2 (0.9)	1 (1.0)	0 (0.0)	3 (0.7)	0.745 <sup>2</sup>
Asthma	10 (10.9)	22 (10.3)	5 (5.0)	5 (3.9)	42 (9.5)	0.307 <sup>2</sup>
COPD <sup>‡</sup>	1 (1.1)	0 (0.0)	1 (1.0)	1 (2.8)	3 (0.7)	0.243 <sup>2</sup>
Immunocompromised	0 (0.0)	2 (0.9)	3 (3.0)	1 (2.8)	6 (1.4)	0.256 <sup>2</sup>
Steroid treatment	0 (0.0)	1 (0.5)	2 (2.0)	2 (5.6)	5 (1.1)	0.032 <sup>2</sup>
Smoking	19 (20.7)	66 (31.0)	34 (33.7)	16 (44.4)	135 (30.5)	0.046 <sup>2</sup>
Alcohol dependence	7 (7.6)	18 (8.5)	18 (17.8)	6 (16.7)	49 (11.1)	0.038 <sup>2</sup>
Drug dependence	0 (0.0)	1 (0.5)	3 (3.0)	3 (8.3)	7 (1.6)	0.002 <sup>2</sup>

<sup>1</sup>One-way ANOVA,<sup>2</sup>Chi-square test,<sup>3</sup>Kruskal-Wallis test,<sup>4</sup>Cochran-Armitage test.

Grouping of patients was based on the number of days from symptom onset to oseltamivir administration: Group 1, ≤2 days; Group 2, 3–7 days; Group 3, 8–14 days; Group 4, &gt;14 days.

\*Median number of days from symptom onset to oseltamivir administration among all study patients.

†Socioeconomic background, based on patient's approximate daily income: 0 = &lt;\$5 US, 1 = \$6–\$10, 2 = \$11–\$15, 3 = \$16–\$25, 4 = \$26–\$40, 5 = &gt;\$40.

‡COPD: chronic obstructive pulmonary disease.

doi:10.1371/journal.pone.0021838.t001

## Materials and Methods

### Study design

INER is a national tertiary care organization that includes a research center devoted to respiratory diseases. INER provides medical services primarily for economically deprived and uninsured populations, many of whom are from the Mexico City Metropolitan area. Medical records of patients with RT-PCR confirmed pandemic H1N1 2009 infections who were treated at the INER between April 1, 2009 and January 31, 2010 and were administered oseltamivir, the only available antiviral drug in the INER during the pandemic period, were retrospectively reviewed. All patients who were administered oseltamivir during the study period were included in this study. The regular dosage and duration of oseltamivir treatment was 150 mg/day for 5 days. However, the duration was extended when deemed necessary because of the patient's clinical conditions.

Clinical data, chest radiologic findings and laboratory findings were reviewed in terms of time from symptom onset to oseltamivir administration. Socioeconomic background of patients was classified into 6 levels based on their daily income. The study patients were divided into the following 4 groups based on the number of days from symptom onset to oseltamivir administration: Group 1 ( $\leq 2$  days), Group 2 (3–7 days), Group 3 (8–14 days), and Group 4 ( $> 14$  days).

The groups were compared in terms of clinical symptoms and findings, severity of the respiratory features and the duration of hospitalization. Severity of respiratory features was classified into three categories: severe pneumonia, mild to moderate pneumonia, or upper respiratory tract involvement without pneumonia. Pneumonia was confirmed on the basis of abnormal shadows on chest radiographs and was considered severe if it required mechanical ventilation, and mild to moderate if it did not. The third category consisted of upper respiratory tract involvement without pneumonia. How these aspects were influenced by the time to oseltamivir administration from symptom onset was subsequently examined.

The study was approved by the Institutional Review Boards of the INER, Mexico and National Center for Global Health and Medicine, Japan. Written informed consent was obtained from all hospitalized study patients or their relatives and verbal consent from all study outpatients was obtained in accordance with the Review Boards in the INER. Investigators kept the datasets in password-protected systems and presented data with the anonymity of study patients.

### Statistical analysis

Statistical analyses were performed by comparing Groups 1 through 4, and testing the linearity of incidence. Patient background data (qualitative and quantitative values) and clinical laboratory

**Table 2.** Clinical features of the study patients on admission.

Variable	Oseltamivir administration				Total	P value*
	Group 1 $\leq 2$	Group 2 3–7	Group 3 8–14	Group 4 $> 14$		
<b>No. of patients (% of all study patients)</b>	<b>n = 92 (20.8%)</b>	<b>n = 213 (48.2%)</b>	<b>n = 101 (22.9%)</b>	<b>n = 36 (8.1%)</b>	<b>n = 422 (100%)</b>	
Abnormal respiratory sounds	17 (18.5)	78 (36.6)	48 (47.5)	13 (36.1)	156 (35.3)	<0.001
Hemoptysis	0 (0.0)	10 (4.7)	14 (13.9)	4 (11.1)	23 (6.3)	<0.001
Abnormal pulmonary shadows <sup>†</sup>	23 (25.0)	121 (56.8)	84 (83.2)	34 (94.4)	262 (59.3)	<0.001
Pneumothorax <sup>†</sup>	0 (0.0)	2 (0.9)	5 (5.0)	2 (5.6)	9 (2.0)	0.004
Pleurisy <sup>†</sup>	0 (0.0)	1 (0.5)	3 (3.0)	2 (5.6)	6 (1.4)	0.005
Chest pain	18 (19.6)	61 (28.6)	31 (30.7)	12 (33.3)	122 (27.6)	0.068
Dyspnea	27 (29.3)	100 (46.9)	70 (69.3)	27 (75.0)	224 (50.7)	<0.001
Cyanosis	2 (2.2)	33 (15.5)	29 (28.7)	11 (30.6)	75 (17.0)	<0.001
Intubation	2 (2.2)	31 (14.6)	26 (25.7)	12 (33.3)	71 (16.1)	<0.001
Vomiting	4 (4.3)	10 (4.7)	4 (4.0)	3 (8.3)	21 (4.8)	0.573
Diarrhea	3 (3.3)	11 (5.2)	6 (5.9)	4 (11.1)	24 (5.4)	0.105
Myalgia	45 (48.9)	112 (52.6)	48 (47.5)	16 (44.4)	221 (50.0)	0.540
Asthenia	7 (7.6)	41 (19.2)	20 (19.8)	10 (27.8)	78 (17.6)	0.006
Cough	62 (67.4)	168 (78.9)	79 (78.2)	31 (86.1)	340 (76.9)	0.027
Purulent sputum	13 (14.1)	36 (16.9)	25 (24.8)	10 (27.8)	84 (19.0)	0.018
Arthralgia	40 (43.5)	119 (55.9)	52 (51.5)	19 (52.8)	230 (52.0)	0.381
Chills	2 (2.2)	25 (11.7)	5 (5.0)	2 (5.6)	34 (7.7)	0.872
Nasal obstruction	16 (17.4)	21 (9.9)	4 (4.0)	1 (2.8)	42 (9.5)	0.001
Sore throat	21 (22.8)	34 (16.0)	11 (10.9)	2 (5.6)	68 (15.4)	0.004
Abdominal pain	0 (0.0)	3 (1.4)	2 (2.0)	0 (0.0)	5 (1.1)	0.568
Conjunctivitis	20 (21.7)	17 (8.0)	5 (5.0)	3 (8.3)	45 (10.2)	0.002

Grouping of patients was based on the number of days from symptom onset to oseltamivir administration: Group 1,  $\leq 2$  days; Group 2, 3–7 days; Group 3, 8–14 days; Group 4,  $> 14$  days.

\*Cochran-Armitage test.

<sup>†</sup>Chest radiological findings.

doi:10.1371/journal.pone.0021838.t002

**Table 3.** Laboratory data and physical findings for study patients at presentation\*.

Variable	Group 1 ≤2			Group 2 3–7			Group 3 8–14			Group 4 >14			P value**
	N	Mean	SD	N	Mean	SD	N	Mean	SD	N	Mean	SD	
WBC (10 <sup>3</sup> /μL) <sup>†</sup>	20	8.19	5.13	101	6.62	3.39	73	7.32	3.99	29	7.89	4.12	0.212
Neutrophil count (10 <sup>3</sup> /μL)	17	5.45	4.53	70	4.67	3.07	45	5.51	4.37	24	4.70	2.73	0.596
Lymphocytes count (10 <sup>3</sup> /μL)	17	0.81	0.51	70	1.12	0.76	45	1.25	0.84	24	1.27	1.11	0.264
RBC (10 <sup>6</sup> /μL) <sup>‡</sup>	16	5.04	0.63	68	4.80	0.62	44	4.76	0.54	22	4.58	0.72	0.161
Hemoglobin (g/dL)	18	14.9	1.42	85	14.06	2.08	63	13.97	1.77	26	13.55	2.26	0.161
Platelets (10 <sup>3</sup> /μL)	19	200.9	48.6	86	186.8	85.4	72	232.9	116.5	29	228.9	107.4	0.021
Albumin (d/dL)	14	4.29	0.46	59	3.86	0.50	41	3.65	0.48	18	3.50	0.72	<0.001
Sodium (mEq/L)	19	137.6	4.5	80	136.5	3.5	62	138.4	4.1	25	138.2	3.9	0.020
Body temperature (°C)	69	37.7	1.0	157	37.4	1.0	75	37.1	0.9	28	37.3	0.9	0.007
Respiratory rate	76	23.1	5.9	171	24.4	7.3	89	25.7	10.2	32	25.6	8.5	0.178
SpO <sub>2</sub> <sup>§</sup>	80	92.3	4.3	182	90.0	7.1	82	85.8	9.6	32	86.1	12.1	<0.001

Grouping of patients was based on the number of days from symptom onset to oseltamivir administration: Group 1, ≤2 days; Group 2, 3–7 days; Group 3, 8–14 days; Group 4, >14 days.

<sup>†</sup>WBC: white blood cell count,

<sup>‡</sup>RBC: red blood cell count,

<sup>§</sup>SpO<sub>2</sub>: oxygen saturation measured by pulse oximetry in room air.

\*Normal ranges are as follows: WBC, 4000–10 000; neutrophil count, 2200–8250; lymphocyte count, 1500–4000; RBC, 3.8–6.5; hemoglobin, 11.5–17.0; platelets, 150–400; albumin, 2.30–3.50; sodium, 138–150; respiratory rate, 12–20 per min in adults; SpO<sub>2</sub>, 92–98% at sea level.

\*\*One-way ANOVA.

SD denotes standard deviation.

doi:10.1371/journal.pone.0021838.t003

values were summarized, and the linearity of incidence of each symptom according to the number of days to oseltamivir administration was analyzed using Cochran-Armitage test. The severity of the respiratory features was analyzed using Jonckheere's test. Severe pneumonia, mild to moderate pneumonia, and upper respiratory tract involvement without pneumonia were handled as ordinal variables and were analyzed using proportional odds models with the time-interval from the symptom onset to the oseltamivir administration as the explanatory and continuous variable [11]. A graph of the probability of severe pneumonia and the probability of mild to severe (any severity) pneumonia, which were estimated by varying the number of days from the symptom onset from 0 to 50 days with the estimated regression coefficient, was depicted. The calculation formula was provided in the figure legend. The multivariate analysis using a proportional odds model was performed to identify profound

factors that affected the severity of respiratory features. The explanatory variables were Groups 1 through 4, the socioeconomic background, gender, age and comorbidities.

The cumulative rate of hospital discharge for Groups 1 through 4 was calculated by Kaplan-Meier's method using mortality data as censored data and then comparatively analyzed using Tarone's test.

Data analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, North Carolina). For all analyses, significance levels were two tailed, and a P value of <0.05 was considered significant.

## Results

### Characteristics of the study patients

Among patients suspected of having pandemic H1N1 2009 virus infection and admitted to the INER during the study period,

**Table 4.** Severity of respiratory features in each group.

Variable	Oseltamivir administration				Total
	Group 1 ≤2	Group 2 3–7	Group 3 8–14	Group 4 >14	
<b>Days from symptom onset until oseltamivir administration</b>					
<b>No. of patients (% of total patients)</b>	<b>n = 92 (20.8%)</b>	<b>n = 213 (48.2%)</b>	<b>n = 101 (22.9%)</b>	<b>n = 36 (8.1%)</b>	<b>n = 442</b>
Severe pneumonia* (% of group)	2 (2.2)	31 (14.6)	26 (25.7)	12 (33.3)	71 (16.1)
Moderate/mild pneumonia† (% of group)	21 (22.8)	90 (42.3)	58 (57.4)	22 (61.1)	191 (43.2)
Upper respiratory tract infection‡ (% of group)	69 (75)	92 (43.2)	17 (16.8)	2 (5.6)	180 (40.7)

(P<0.001, Jonckheere's test).

Grouping of patients was based on the number of days from symptom onset to oseltamivir administration: Group 1, ≤2 days; Group 2, 3–7 days; Group 3, 8–14 days; Group 4, >14 days.

\*Severe pneumonia: abnormal shadows on chest radiographs and required mechanical ventilation.

†Moderate/mild pneumonia: abnormal shadows on chest radiographs but did not require mechanical ventilation.

‡Upper respiratory tract infection: absence of pneumonia.

doi:10.1371/journal.pone.0021838.t004

528 were confirmed to have pandemic H1N1 2009 virus infection by RT-PCR. There were no resistant viral strains involved in this study. Of these 528 patients, 442 received oseltamivir treatment during either ambulatory care (45.5%) or hospitalization (54.5%), these included 24 individuals who died. The 442 patients comprised the study subjects from whom clinical data were collected. Their characteristics are shown in Table 1. Data were obtained at the time of patients' presentation to the INER before oseltamivir administration. Median days from symptoms onset to oseltamivir administration was 5.0 (range, 0–43). Groups 1, 2, 3, and 4 comprised 92 (20.8%), 213 (48.2%), 101 (22.9%), and 36 (8.1%) patients, respectively.

Median age of study patients (193 females and 249 males) was 36 years with a range of 4 months to 85 years. Of the 442 study patients, 75 (17%) were aged <18 years, and 292 (66.1%) were aged 18 to 50 years. A total of 399 (90.3%) earned less than \$15 US per day (<level 2). Only 11 (2.5%) had a history of vaccination for seasonal influenza in 2008 and/or 2009. The number of hospitalized patients ( $P<0.001$ ), mortality ( $P=0.004$ ), older age ( $P=0.01$ ), and lower socioeconomic level ( $P=0.001$ ) were associated with the Groups. The presence of comorbidities was not associated with the Groups; however, smoking ( $P<0.05$ ), drug dependency ( $P=0.002$ ), and alcohol dependency ( $P<0.04$ ) were associated.

Symptoms of the study patients were shown in Table 2. The main symptoms were cough (76.9%), arthralgia (52.0%), dyspnea (50.7%), myalgia (50.0%), purulent sputum (19.0%), cyanosis (17.0%), and sore throat (15.4%). A total of 59% of study patients had pneumonia with abnormal shadows on chest radiographs, and 16% required mechanical ventilation.

Clinical symptoms and findings that increased significantly with time to oseltamivir administration ( $P<0.05$ ) were included

abnormal respiratory sounds; hemoptysis; abnormal pulmonary shadows, pneumothorax and pleurisy on chest radiographs; dyspnea; cyanosis; and need for intubation. On the other hand, incidence of nasal obstruction, sore throat, and conjunctivitis decreased as the time to oseltamivir administration increased.

Among the laboratory findings (Table 3), oxygen saturation ( $SpO_2$ ) measured by pulse oximetry decreased significantly as the time to oseltamivir administration increased. Although within the normal range, serum albumin decreased significantly, and serum sodium, platelets, and body temperature differed significantly among the Groups.

### Severity of respiratory features

Severe pneumonia was present in 71 (16.1%) patients. Mild to moderate pneumonia was present in 191 (43.2%), and upper respiratory tract involvement without pneumonia was present in 180 (40.7%) (Table 4).

The proportions of patients with severe pneumonia or mild to moderate pneumonia increased from Groups 1 to 4 (Table 4). By the contrast, the proportions of patients with upper respiratory tract infection without pneumonia decreased from Groups 1 to 4. These results indicated that the severity of respiratory features reflected the time to oseltamivir administration ( $P<0.001$ , Jonckheere's test).

The results obtained by the multivariate analysis using a proportional odds model indicated that severity of respiratory features was also affected by socioeconomic level, gender, hypertension, obesity, asthma and smoking (Table 5). The proportional odds ratios for severities of respiratory features for Groups 2–4 were 5.17, 15.02, and 20.40 times higher, respectively, than that for Group 1. The grouping, which indicated days to oseltamivir administration, showed a high level of significance in terms of the severity of respiratory features.

**Table 5.** Multivariate analysis of the severity of respiratory features using a proportional odds model.

Parameter	Regression coefficient	Standard error	$\chi^2$	P value	Reference group	Odds ratio and 95% confidence interval
Intercept 1	4.42	1.62				
Intercept 2	7.39	1.66				
Group 2* 3–7	1.64	0.30	29.49	<0.001	vs Group 1*	5.17 (2.86–9.37)
Group 3* 8–14	2.70	0.35	59.59	<0.001	vs Group 1*	15.02 (7.55–29.89)
Group 4* >14	3.01	0.44	45.33	<0.001	vs Group 1*	20.40 (8.48–49.10)
Socioeconomic category <sup>†</sup>	–0.49	0.12	15.91	<0.001	– <sup>†</sup>	0.60 (0.47–0.77)
Gender (female)	0.80	0.21	14.03	<0.001	vs male	2.23 (1.46–3.40)
AGE 2 <sup>‡</sup>	0.37	0.29	1.60	0.205	vs AGE 1 <sup>‡</sup>	1.45 (0.81–2.59)
AGE 3 <sup>‡</sup>	0.94	0.37	6.35	0.011	vs AGE 1 <sup>‡</sup>	2.57 (1.23–5.38)
Diabetes <sup>§</sup>	–0.34	0.43	0.64	0.424	vs present	0.70 (0.30–1.65)
Hypertension <sup>§</sup>	–0.85	0.36	5.37	0.020	vs present	0.42 (0.20–0.87)
Obesity <sup>§</sup>	–1.76	0.32	29.52	<0.001	vs present	0.17 (0.09–0.32)
Asthma <sup>§</sup>	–1.04	0.34	8.99	0.002	vs present	0.35 (0.17–0.69)
Smoking <sup>§</sup>	–0.73	0.24	9.16	0.002	vs present	0.47 (0.29–0.77)
Alcoholism <sup>§</sup>	0.22	0.34	0.42	0.515	vs present	1.25 (0.63–2.44)

\*Grouping of patients was based on the number of days from symptom onset to oseltamivir administration: Group 1,  $\leq 2$  days; Group 2, 3–7 days; Group 3, 8–14 days; Group 4, >14 days.

<sup>†</sup>The odds ratio of socioeconomic level was presented when the level was upped by one unit as a continuous variable.

<sup>‡</sup>AGE 1 (age <18 y), AGE 2 (age 18–50 y), AGE 3 ( $\geq 50$  y).

<sup>§</sup>Comorbidities are compared between present and absent.

$\chi^2$ : Chi-square test.

doi:10.1371/journal.pone.0021838.t005

### Occurrence of pneumonia

The number of patients who developed radiographic pneumonia was 262 (59.3%). The probability of pneumonia occurrence was estimated in relation to time from symptom onset using a proportional odds model (Figure 1). Figure 1 shows the time to occurrence of pneumonia. Both the probability of any severity of pneumonia and the probability of severe pneumonia increased gradually with the time from symptom onset to oseltamivir administration. The 50% probability for occurrence of any severity of pneumonia and that of severe pneumonia in patients who would develop pneumonia reached at approximately 3.4 and 21 days, respectively, after symptom onset.

### Duration of hospitalization


Of the 442 patients evaluated, 241 (54.5%) were hospitalized. The numbers of hospitalized patients in each group are shown in Table 1. The cumulative discharge rate in each group on a Kaplan-Meier's curve using death data as censored data is shown in Figure 2. Patients with a shorter time to oseltamivir administration were discharged earlier from the hospital ( $p < 0.001$ , Tarone's test).

### Discussion

Severe pneumonia caused by pandemic H1N1 2009 has been frequently found [1,3,7,8,9,12,13]. Severity of pneumonia can be assumed to be a main indicator of overall disease severity. We hypothesized that the number of days to oseltamivir administration from symptom onset was one of the primary factors affecting the severity of pneumonia due to pandemic H1N1 2009.

Patients with pandemic H1N1 2009 infection in the INER had various time-intervals between the symptom onset and oseltamivir administration. Median days from symptom onset to oseltamivir administration was 5.0 (range 0–43) (Table 1), even though 92.5% of study patients was administered oseltamivir within one day after admission (median 0, range 0–12).

The study findings indicated that the following symptoms and clinical findings, associated with the severity of illness, increased significantly with the number of days to oseltamivir administration: abnormal respiratory sounds; hemoptysis; pulmonary infiltrative shadows, pneumothorax and pleurisy on chest radiographs; dyspnea; cyanosis; and need for intubation (Table 2). Conversely, SpO<sub>2</sub> decreased with time to oseltamivir administration, as did the incidence of upper respiratory tract symptoms, including nasal



**Figure 1. Model of the probability of occurrence of pneumonia.** The probability of developing pneumonia is depicted using a proportional odds model.  $p_1$ , the probability of severe pneumonia;  $p_2$ , the probability of mild/moderate pneumonia;  $x$ , time until oseltamivir administration from symptom onset.


$$p_1 = \exp(-2.7313 + 0.1281 x) / (1 + \exp(-2.7313 + 0.1281 x))$$

$$p_1 + p_2 = \exp(-0.4301 + 0.1281 x) / (1 + \exp(-0.4301 + 0.1281 x))$$

Parameter, estimated value (standard error): intercept 1, -2.7313 (0.2047); intercept 2, -0.4301 (0.11449); slope of  $x$ , 0.1281 (0.0179). [ $\chi^2$  value = 51.41,  $p < 0.001$ ].

The solid line indicates the probability of occurrence of severe pneumonia ( $p_1$ ). The dotted line indicates the probability of occurrence of any severity of pneumonia (mild to severe pneumonia,  $p_1 + p_2$ ).

doi:10.1371/journal.pone.0021838.g001



**Figure 2. Cumulative rate of hospital discharge as a function of the time of oseltamivir administration.** The cumulative rate of hospital discharge in each group using Kaplan-Meier's method was calculated using data on death as censored data. The groups of patients with earlier oseltamivir administration were discharged from the hospital significantly earlier ( $p < 0.001$ , Tarone's test). Grouping of patients was based on days from symptom onset to oseltamivir administration: Group 1,  $\leq 2$ ; Group 2, 3-7; Group 3, 8-14; Group 4,  $> 14$  days. doi:10.1371/journal.pone.0021838.g002

obstruction, sore throat and conjunctivitis (Table 3). These findings suggest that the viral infection began in the upper respiratory tract and descended to the lower respiratory tract, and then the virus proliferated in the alveolar lung tissues in most pneumonia.

In this study, severity of respiratory features ranged from upper respiratory tract involvement without pneumonia to severe pneumonia. The proportions of patients with severe pneumonia and mild to moderate pneumonia increased from Groups 1 to 4. (Table 4). By contrast, the proportions of patients with upper respiratory tract involvement without pneumonia decreased from Groups 1 to 4. The association between severity of respiratory features and time to oseltamivir administration was found to be highly significant even after adjusting for socioeconomic levels, gender, hypertension, obesity, asthma and smoking (Table 5). Analysis of the probabilities of developing pneumonia indicated that the occurrence of any severity of pneumonia as well as that of severe pneumonia was associated with a longer interval from symptom onset to oseltamivir administration (Figure 1). The probability of occurrence of any severity of pneumonia was 50% at 3.4 days. The probability of severe pneumonia increased gradually and was approximately 10% at 3 days after symptom onset. These results indicate that early initiation of oseltamivir administration after the symptom onset is the significant factor for the reduction of severity of pneumonia. The probability of occurrence of severe pneumonia and any severity of pneumonia at 48 hours were  $< 10\%$  and  $< 50\%$ , respectively, and increased gradually in this study. The estimations suggest that oseltamivir administration, even  $> 2$  days following symptom onset, still had considerable

potential for reducing the occurrence of pneumonia of any severity. This study also found that the shorter the delay in starting oseltamivir, the shorter the length of hospitalization (Figure 2). This finding is compatible with previous studies [14,15].

Oseltamivir is a neuraminidase inhibitor that prevents cleavage of sialic acid on the surfaces of host cells, thus preventing new viral particles from being released by infected cells [10]. Viral neuraminidase is also known to play a role in the initial stages of airway epithelial cell infection [16] and to assist in hemagglutinin fusion [17]. Therefore, oseltamivir reduces viral cell entry as well as release. Seasonal influenza has been shown to replicate in humans for approximately 7 days post infection [18]. In pandemic H1N1 2009, it is likely that either the virus had an evasive phenotype [19] or the patient was predisposed to severe disease. This may lead to the assumption that patients who respond to oseltamivir at a later time after symptom onset still harbor actively replicating influenza virus [20]. This study might include patients who had difficulty in controlling influenza virus replication once it had taken hold within patients' bodies. The study also might constitute the population who has various host responses to the novel H1N1 influenza virus.

An important issue revealed in this study is the late access to medical care in Mexico. One of the main reasons for this may have been the cost consciousness of the patients; another may have been a lack of education. Such issues may have strongly influenced the severity of illness and need to be further investigated.

The present study has several limitations. First, the study was retrospective and there were no clear criteria for oseltamivir



administration when patients presented. Second, there were also patients who were not administered oseltamivir and were excluded from this study. Since we only included patients administered oseltamivir, there is a potential bias. Most patients with influenza recovered without antiviral treatment. The study patients, who visited the INER, were likely to be representative of those patients with more severe disease. Third, some patients may have had secondary bacterial infection in addition to primary viral infection [3]. This study was also unable to evaluate bacterial infection or antibiotic treatments because of insufficient data.

Regardless, the findings of this study will be valuable across many fields of medicine, science, and public health. Clinically, the present results support the initiation of treatment as soon as a patient presents, regardless of whether 48 hours have passed since disease onset. In addition, the effect of oseltamivir on the occurrence and severity of pneumonia shows that inhibition of infection of new cells is linked to better clinical outcomes. Moreover, these findings will help planning for future pandemics and may result in an increase in the availability of oseltamivir treatment to individuals in the community who have not recovered significantly after 2 days when afflicted with influenza-like illness.

In conclusion, the present findings indicate that earlier initiation of oseltamivir administration after symptom onset significantly reduced the occurrence and severity of pneumonia and shortened

the length of hospitalization in patients with pandemic H1N1 2009. In addition, even when administered >48 hours after symptom onset, oseltamivir showed considerable potential to reduce the occurrence and severity of pneumonia. The results from this retrospective study which indicated the effectiveness of earlier administration of antiviral agents at any time after symptom onset for reducing the occurrence of pneumonia should benefit patients affected by the next influenza pandemic. However, continued investigation and further prospective studies to more fully define the effectiveness of early antiviral treatment are required.

## Acknowledgments

The authors thank Kimio Abe for supporting the statistical analysis and Takuro Shimbo, Kenji Yamamoto, Fumihide Kanaya and Matias Vera for cooperating with this work. The authors also thank Angela Morben for editorial assistance.

## Author Contributions

Conceived and designed the experiments: ALHI KK. Performed the experiments: ALHI KK TM AECB ACB LAR RGG MEMZ JT SI EB JRPP. Analyzed the data: ALHI KK TM. Wrote the paper: KK TM.

## References

- Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quiñones-Falconi F, et al. (2009) Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. *N Engl J Med* 361: 680–689.
- World Health Organization (2010) Pandemic (H1N1) 2009 – update 94. Available: [http://www.who.int/csr/don/2010\\_4\\_23a/en/index.html](http://www.who.int/csr/don/2010_4_23a/en/index.html). Accessed 2010 April 24.
- Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, et al. (2010) Clinical aspects of Pandemic 2009 Influenza A (H1N1) virus infection. *N Engl J Med* 362: 1708–1719.
- SALUDE (2010) Situación actual de la epidemia. Available: <http://portal.salud.gob.mx/contenidos/noticias/influenza/estadisticas.html>. Accessed 2010 September 1. (In Spanish.)
- World Health Organization (2010) WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. Available: [http://www.who.int/csr/resources/publications/swineflu/h1n1\\_guidelines\\_pharmaceutical\\_mngt.pdf](http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf). Accessed 2010 September 1.
- Centers for Disease Control and Prevention (2010) Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009–2010 season. Available: <http://www.cdc.gov/h1n1flu/recommendations.htm>. Accessed 2010 July 29.
- The ANZIC Influenza Investigators, Webb SA, Pettit V, Seppelt I, Bellomo R, Bailey M, et al. (2009) Critical care services and 2009 H1N1 influenza in Australia and New Zealand. *N Engl J Med* 361: 1925–1934.
- Louie JK, Acosta M, Winter K, Jean C, Gavali S, et al. (2009) Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. *JAMA* 302: 1896–1902.
- Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, et al. (2009) Critically ill patients with 2009 influenza A (H1N1) infection in Canada. *JAMA* 302: 1872–1879.
- Roche Laboratories, Inc. (2010) Tamiflu product information. Prescribing information document from Roche. Last updated September 2010. Available: <http://www.gene.com/gene/products/information/tamiflu/pdf/pi.pdf>. Accessed 2010 December 3.
- Alan Agresti (2010) Analysis of Ordinal Categorical Data, 2nd Edition. April 2010, Wiley.
- Dominguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, et al. (2009) Critically ill patients with 2009 influenza A(H1N1) in Mexico. *JAMA* 302: 1880–1887.
- Shieh WJ, Blau DM, Denison AM, DeLeon-Carnes M, Adem P, et al. (2010) 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. *Am J Pathol* 177: 166–175.
- Centers for Disease Control and Prevention (2010) Patients hospitalized with 2009 pandemic influenza A (H1N1) – New York City, May 2009. *MMWR Morb Mortal Wkly Rep* 58: 1436–1440.
- Lee N, Choi KW, Chan PK, Hui DS, Lui GC, et al. (2010) Outcomes of adults hospitalised with severe influenza. *Thorax* 65: 510–515.
- Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD (2004) Neuraminidase is important for the initiation of influenza virus infection of human airway epithelium. *J Virol* 78: 12665–12667.
- Su B, Wurtzer S, Rameix-Welti MA, Dwyer D, van der Werf S, et al. (2009) Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase. *PLoS One* 4: e8495.
- Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, et al. (1998) Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. *J Clin Invest* 101: 643–649.
- Safronetz D, Rockx B, Feldmann F, Belisle SE, Palermo RE, et al. (2010) Pandemic swine-origin H1N1 influenza A virus isolates show heterogeneous virulence in macaques. *J Virol* doi:10.1128/JVI.01848-10. (Online published ahead of print.) Accessed 2011 January 8.
- To KK, Hunh IF, Li IW, Lee K-L, Koo C-K, et al. (2010) Delayed clearance of viral load and marked cytokine action in severe cases of pandemic H1N1 2009 influenza virus infection. *Clin Infect Dis* 50: 850–9.



# Guidelines for Diagnosis and Treatment of Myocarditis (JCS 2009)

– Digest Version –

JCS Joint Working Group

## Table of Contents

Revision of the Guidelines.....	734	3. Eosinophilic Myocarditis.....	739
I Classification, Diagnosis and Treatment of Acute Myocarditis .....	734	4. Chronic Myocarditis .....	739
1. Etiology .....	734	5. Pediatric Myocarditis.....	739
2. Classification .....	735	6. Neonatal Myocarditis .....	739
3. Symptoms, Signs and Clinical Tests.....	735	III Diseases Similar to Myocarditis .....	740
4. Methods of Diagnosis and Evaluation.....	735	1. Cardiac Sarcoidosis .....	740
5. Treatment.....	736	2. Autoimmune Myocarditis (Myocarditis Derived From Collagen Diseases).....	741
6. Prognosis and Natural History .....	738	3. Drug-Induced Myocarditis .....	741
II Diagnosis and Treatment of Specific Types of Myocarditis.....	738	IV Conclusion .....	741
1. Fulminant Myocarditis .....	738	References .....	741
2. Giant Cell Myocarditis .....	738		

(*Circ J* 2011; **75**: 734–743)

## Revision of the Guidelines

Myocarditis is an inflammatory condition mainly located in the myocardium. Its incidence and mortality in the Japanese population have not been determined, since definitive diagnosis of myocarditis is difficult. These “Guidelines for Diagnosis and Treatment of Myocarditis” have been compiled based on basic and clinical research on myocarditis which has been conducted using sound scientific methods in Japan, though

the evidence obtained may not qualify as that of evidence-based medicine. In the guidelines, cardiac magnetic resonance (CMR) imaging is considered valuable as an effective means of diagnosis of myocarditis. In addition, information on cardiac sarcoidosis, autoimmune myocarditis, and drug-induced myocarditis is included.

## I Classification, Diagnosis and Treatment of Acute Myocarditis

### 1. Etiology

Myocarditis is caused by a variety of bacterial and viral infections. Enteroviruses, especially coxsackievirus B, are often associated with acute myocarditis.<sup>1</sup> However, with the advent of genetic analysis, adenovirus and parvovirus B19 have also been found to be frequent causes of myocarditis.<sup>2</sup>

Exposure to drug treatment, physical stimuli such as radiation and heat, metabolic disorders, immune disorders, and pregnancy are also causes of myocarditis. In the case of idiopathic myocarditis, the etiology is yet to be determined.

Released online February 4, 2011

Mailing address: Scientific Committee of the Japanese Circulation Society, 8th Floor CUBE OIKE Bldg., 599 Bano-cho, Karasuma Aneyakoji, Nakagyo-ku, Kyoto 604-8172, Japan. E-mail: [meeting@j-circ.or.jp](mailto:meeting@j-circ.or.jp)

This English language document is a revised digest version of Guidelines for Diagnosis and Treatment of Myocarditis reported at the Japanese Circulation Society Joint Working Groups performed in 2008 (website: [http://www.j-circ.or.jp/guideline/pdf/JCS2009\\_izumi\\_d.pdf](http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_d.pdf)).

Joint Working Groups: The Japanese Circulation Society, The Japanese Association for Thoracic Surgery, The Japanese Society of Pediatric Cardiology and Cardiac Surgery, The Japanese Society for Cardiovascular Surgery, The Japanese College of Cardiology, The Japanese Heart Failure Society

ISSN-1346-9843 doi:10.1253/circj.CJ-88-0008

All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: [cj@j-circ.or.jp](mailto:cj@j-circ.or.jp)

## 2. Classification

Myocarditis is classified by its etiology, cell type (lymphocytic type, giant cell type, eosinophilic type, granulomatous type), and clinical type (fulminant type, acute type, chronic type) as shown in Table 1.<sup>3,4</sup>

## 3. Symptoms, Signs and Clinical Tests

### 1 Symptom

Myocarditis is preceded by flu-like symptoms (chills, fever, headache, muscle aches, general malaise) or gastrointestinal symptoms such as decreased appetite, nausea, vomiting, and diarrhea. Cardiac manifestations of myocarditis appear a few hours to a few days after the initial signs and symptoms.<sup>5</sup> Cardiac symptoms consist of (1) those of heart failure, (2) chest pain due to pericardial irritation, and (3) symptoms associated with heart block and arrhythmia. The possibility of myocarditis must be considered if a patient with such symptoms is febrile.

### 2 Sign

The clinical signs of myocarditis include fever, cardiac rhythm disturbance (tachycardia, bradycardia, and arrhythmia), hypotension, gallop rhythm, rales, jugular venous dilatation, and cardiac tamponade.

### 3 Blood Biochemistry

Myocarditis is confirmed by the findings of transient elevation of C-reactive protein (CRP), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), the MB form creatine kinase (CK-MB), and cardiac troponin T in blood.<sup>6</sup> Troponin T, which can be measured quickly and easily in whole blood by enzyme-linked immunosorbent assay (ELISA), is especially useful for immediate diagnosis. However, which type of troponin, T or I, is more useful for diagnosis has not been determined.<sup>7</sup>

### 4 Chest X-Ray

A chest X-ray is useful for visualizing cardiac enlargement and pulmonary congestion.

### 5 Electrocardiography (ECG)

The ECG is a sensitive and convenient means of diagnosis of myocarditis. It must be timely repeated, since minor abnormalities in the ECG detected initially may become clearer over time. Abnormal ST-T waves and conduction block are frequently observed in myocarditis. A gradual increase in the width of the QRS complex is a sign of exacerbation of myocarditis. Continuous ECG monitoring is crucial to detect potentially fatal arrhythmias.

### 6 Echocardiography

Myocarditis can be confirmed by transient wall thickening, reduced wall motion and reduced cardiac chamber size in addition to pericardial effusion on echocardiography.<sup>8</sup> Echocardiography is especially useful for pediatric patients.

### 7 Cardiac Magnetic Resonance (CMR)

In addition to the cinematic mode on magnetic resonance imaging (MRI), T1-weighted early signal enhancement and gadolinium-delayed imaging of the heart are useful to make a positive diagnosis of myocarditis.<sup>9-11</sup> T2-weighted images

Table 1. Myocarditis Classification

Etiology	Cell type	Clinical type
Virus	Lymphocytic type	Acute
Bacteria	Giant cell type	Fulminant
Fungi	Eosinophilic type	Chronic
Rickettsia	Granulomatous type	(prolonged)
Spirochetes		(latent)
Protozoa, parasites		
Other causes of infection		
Drugs, chemical substances		
Allergy, autoimmune		
Collagen disease, Kawasaki disease		
Sarcoidosis		
Radiation, heat stroke		
Unknown cause, idiopathic		

reveal the regions of the heart affected by inflammation. CMR imaging can differentiate acute myocarditis from acute myocardial infarction; acute myocarditis exhibits erosive or spotty areas in the epicardium, while lesions of acute myocardial infarction spread from the endocardium like a wave front.

### 8 Nuclear Medicine Techniques

In gallium-67 (<sup>67</sup>Ga) myocardial imaging, <sup>67</sup>Ga uptake in the myocardium is highly specific for detection of myocarditis, though this method is not highly sensitive.<sup>12</sup> On the other hand, technetium-99m (<sup>99m</sup>Tc) pyrophosphate myocardial scintigraphy has relatively high sensitivity but is not specific.<sup>13</sup>

### 9 Cardiac Catheterization Including Endomyocardial Biopsy

Cardiac catheterization may be performed in the acute phase of myocarditis if the patient's condition allows. After coronary lesion has been excluded, an endomyocardial biopsy should be performed to detect myocardial degeneration, myocyte necrosis, inflammatory infiltrates, and/or interstitial edema of the myocardium. Even if the results are negative, the presence of myocarditis cannot be excluded due to the possibility of sampling errors.<sup>14</sup> Biopsy sampling at three or more different sites is therefore strongly recommended.<sup>15</sup>

### 10 Diagnosis of Viral Infection

Viral infection is confirmed if the viral antibody titer is at least four times higher in an acute phase serum sample than in a sample obtained in remission phase collected at least two weeks apart. However, only approximately 10% of patients with viral infection exhibit a positive antibody titer. Polymerase chain reaction (PCR) is more useful for identifying the genomes of viruses causing myocarditis, but is not commonly performed.<sup>16</sup>

## 4. Methods of Diagnosis and Evaluation

Clinical diagnosis of myocarditis should be performed following the "Diagnostic guidelines for acute myocarditis"<sup>17</sup> (Table 2).

**Table 2. Diagnostic Guidelines for Acute Myocarditis**

1. In acute myocarditis, flu-like signs and symptoms<sup>a)</sup>, gastrointestinal signs and symptoms<sup>b)</sup>, skin rash, joint pain, or muscle pain may occur before cardiac signs and symptoms<sup>c)</sup>. However, sudden death may occur without preceding clinical signs.
2. Cardiac findings such as tachycardia, bradycardia, arrhythmia, weakened heart sounds, gallop rhythm (III, IV), pericardial rub, and systolic murmur occur.
3. Generally, an abnormal ECG is observed during the course of myocarditis. ECG manifestations are diverse, and include atrioventricular block (I to III degree), intraventricular conduction delay (widened QRS complex), reduced R wave height, abnormal Q waves, ST-T segment changes, low voltage, frequent premature beats, supraventricular tachycardia, atrial fibrillation, sinus arrest, ventricular tachycardia, ventricular fibrillation, and asystole.
4. Localized or diffuse wall thickening, reduced wall motion, reduced cardiac chamber size, and pericardial effusion are found on echocardiography.
5. In myocarditis, myocardial constitutive proteins (cardiac troponin T and creatine kinase-MB) are detected in serum. C-reactive protein and white blood cell count are elevated. Early detection of troponin T using whole blood enables immediate diagnosis of myocarditis.
6. Since the conditions in items 2 and 5 above may progress within a few hours, changes over time in these conditions should be followed. If a patient has bradycardia, widened QRS complex, frequent premature beats, wall thickening, exacerbation of reduced wall motion, elevated troponin T, and continuous increase in troponin T level, the patient may have a cardiopulmonary emergency.
7. Definitive diagnosis of myocarditis requires that acute myocardial infarction be excluded.
8. The presence of abnormal histological findings on endomyocardial biopsy<sup>d)</sup> makes the diagnosis of myocarditis definite. However, the absence of such findings does not exclude the possibility of myocarditis.
9. Elevation of viral titer in a sample collected in the acute phase to at least four times that in a sample obtained in remission is useful for identify viral infection as the cause. Polymerase chain reaction is often used to demonstrate the presence of viral infection and to detect the viral genome. Separation of virus or identification of virus by antibody titer in throat swabs, urine, feces, blood, and especially pericardial effusion or cardiac muscle tissue provides direct evidence of myocarditis.

<sup>a)</sup> Flu-like symptoms: Fever, headache, cough, and throat pain.

<sup>b)</sup> Gastrointestinal symptoms: Nausea, vomiting, stomach ache, and diarrhea.

<sup>c)</sup> Cardiac symptoms: Chest pain, syncope, dyspnea, palpitations, shock, seizure, and cyanosis.

<sup>d)</sup> See Table 3.

ECG, electrocardiography.

Adapted from the Ministry of Health and Welfare (MHW) Specific Disease Idiopathic Cardiomyopathy Study Group Report in 1986. 1987; 13–14.

If acute myocardial infarction is excluded but active lesions of myocarditis can be confirmed on endomyocardial biopsy<sup>18</sup> (Table 3), myocarditis is considered definitively diagnosed.

## 5. Treatment

The primary signs and symptoms and disease progression of myocarditis are relatively easy to grasp. The inflammatory phase lasts one to two weeks, and is followed by a recovery phase. Myocarditis causes myocardial necrosis and inflammation, which result in cardiac dysfunction and failure. Myocarditis is therefore treated in three ways: (1) intervention to eliminate the cause, (2) intervention to improve hemody-

**Table 3. Diagnostic Criteria for Acute Myocarditis in Endomyocardial Biopsy**

1. Infiltration of many large or small mononuclear cells\* (occasionally, a few polymorphonuclear leukocytes and multinucleated giant cells appear)
2. Rupture, fusion and disappearance of cardiomyocytes
3. Interstitial edema (occasionally with fibril formation)

\*Cell infiltrates are often observed adjacent to cardiomyocytes.

Factors involved in definitive diagnosis of myocarditis.

1. Endomyocardial biopsy may be performed after the occurrence of symptoms suggestive of viral infection.

2. Repeated biopsies over time are useful for determining the pathology and the effects of treatment.

3. Biopsy sampling from at least 3 sites is strongly recommended. The samples should be obtained from different angles.

4. Detailed findings can be obtained by electron microscopy and immunohistochemical methods.

Adapted from the MHW Specific Disease Idiopathic Cardiomyopathy Study Group Report in 1988. 1989; 181–182.




Figure 1. Course of cardiac dysfunction and timing of intervention in myocarditis.

namic compromise, and (3) intervention in cardiac dysfunction (Figure 1).

### 1 Treatment of Asymptomatic or Mildly Symptomatic Myocarditis

Patients with asymptomatic or mildly symptomatic myocarditis with cardiac signs and symptoms should be admitted to the hospital, kept at bed rest, and monitored carefully. A regimen for cardiopulmonary emergency must be prepared beforehand, in the event of acute changes.

### 2 Treatment of Arrhythmia


Patients with arrhythmia caused by severe heart block should temporarily be treated with external pacing. However, use of drugs must be avoided in case of frequent premature beats and nonsustained in patients with ventricular tachycardia.

### 3 Management of Heart Failure

For patients with cardiac pump failure in the acute phase, use of catecholamines or carperitide is recommended. If the patient does not respond to treatment, a circulatory assist device should be used.

### 4 Additional Treatment for Refractory Myocarditis

In patients with persistent inflammation without signs of hemodynamic improvement, short-term treatment with large doses of corticosteroids may be attempted.<sup>19</sup> There are cases of



**Figure 2.** PCPS management of fulminant myocarditis. PCPS, percutaneous cardiopulmonary support; CPR, cardiopulmonary resuscitation; PDE, phosphodiesterase; IABP, intra-aortic balloon pump; ACT, activated coagulation time; SVO<sub>2</sub>, mixed venous oxygen saturation; LA, lactic acidosis; TB, tuberculosis; AKBR, arterial ketone body ratio; EF, ejection fraction; FS, fractional shortening; CCI, cerebral circulatory index; ETCO<sub>2</sub>, end-tidal carbon dioxide; CVVH, continuous veno-venous hemofiltration; DIC, disseminated intravascular coagulation; Hb, hemoglobin; Plt, platelet count; G-I, glucose-insulin; PA, pression arterielle; PaCO<sub>2</sub>, partial pressure of carbon dioxide. Modified from *Circ J* 2002; **66**: 133–144.

remarkable recovery. Treatment with high dose immunoglobulin may also be considered.<sup>20</sup>

### 5 Management of Myocarditis in the Recovery Phase

Treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers can be performed to protect the myocardium.

## 6. Prognosis and Natural History

In the acute phase, myocarditis management of cardiac pump failure and potentially fatal arrhythmias is the main clinical challenge. The prognosis of myocarditis varies depending on the pathogenesis and type of disease.<sup>21</sup>

## II Diagnosis and Treatment of Specific Types of Myocarditis

### 1. Fulminant Myocarditis

#### 1 Background

Fulminant myocarditis causes acute hemodynamic compromise which may prove fatal. External circulatory support is required to save the patient's life.

#### 2 Diagnosis

The initial evidence of fulminant myocarditis is very similar to that of acute myocarditis, with cardiac shock and circulatory failure as the main crucial points to be handled. On blood chemistry test, blood cardiac troponin is of chief importance for diagnosis.<sup>22</sup> A continuous decrease in the cardiac troponin level suggests that the patient is stabilizing. Changes over time in the ECG are important, since widening of the QRS complex and frequent ventricular arrhythmia indicate that myocarditis is following a fulminant course.<sup>23</sup> Patients with fulminant myocarditis often have a reduced left ventricular ejection fraction. Monitoring of progressive concentric wall thickening and reduction of wall motion in echocardiography over time is important.<sup>8</sup> Fulminant myocarditis can not be identified by histology. Hemodynamics must be continuously evaluated always with echocardiography and guided often by Swan-Ganz catheterization in serious cases.

#### 3 Treatment

Management of acute fulminant myocarditis should focus on prevention of hemodynamic which have been compromised and bridging the patient to natural recovery.<sup>24</sup> Intra-aortic balloon pump (IABP), percutaneous cardiopulmonary support (PCPS), and left ventricular assist device (LVAD) are available as circulatory assistance. Circulatory support should be performed for potentially fatal arrhythmias and low cardiac output. When such devices are used, the following are of great importance: (1) selection of device and timing of introduction, (2) assist volume setting, and (3) prevention of complications<sup>4</sup> (Figure 2). In patients refractory to such support, treatment with immunosuppressant may be acceptable. When cardiac dysfunction or heart block does not improve within 3 to 4 days after the initial signs and symptoms of fulminant myocarditis, brief treatment with high-dose corticosteroids or high-dose immunoglobulin may be considered.

### 2. Giant Cell Myocarditis

#### 1 Background

The clinical presentation of giant cell myocarditis tends to be similar to that of fulminant myocarditis.<sup>25</sup> Allergy and/or autoimmune factors are thought to be involved in giant cell myocarditis.

**Table 4. Diagnostic Guidelines for Eosinophilic Myocarditis**

If the five minimally required conditions listed below are observed in a patient, eosinophilic myocarditis should be strongly suspected. However, acute myocardial infarction must be excluded by coronary angiography. The diagnosis of eosinophilic myocarditis must be confirmed by endomyocardial biopsy.

#### 1. Minimally required conditions

- 1) Increased eosinophil count in peripheral blood ( $\geq 500/\text{mm}^3$ )<sup>a)</sup>
- 2) Chest pain, dyspnea, and cardiac symptoms such as palpitations
- 3) Elevated enzymes indicating myocardial injury, including creatine kinase-MB and the myocardial constitutive protein, including cardiac troponin T
- 4) ECG changes<sup>b)</sup>
- 5) Transient left ventricular wall thickening<sup>c)</sup> and abnormal wall motion on echocardiography

#### 2. Useful information

- 1) Approximately one-third of patients with eosinophilic myocarditis have allergic conditions (such as bronchial asthma, rhinitis and urticaria).
- 2) Approximately two-thirds of patients with eosinophilic myocarditis have previous flu-like symptoms (such as fever, sore throat and cough).

#### 3. Endomyocardial biopsy

Histological findings in eosinophilic myocarditis include eosinophil infiltrates, degranulation of eosinophils, disappearance and fusion of cardiomyocytes, and interstitial edema and fibrosis. Occasionally, endocarditis is observed.

<sup>a)</sup> Some patients have an increased eosinophil count in peripheral blood before cardiac symptoms appear, and some patients have cardiac symptoms with a normal eosinophil count, which gradually increases to above  $500/\text{mm}^3$ . In the acute phase, the eosinophil count must be determined every 2 to 3 days. However, the eosinophil count increases in a different way in each patient.

<sup>b)</sup> ST elevation is observed in approximately 50% and abnormal Q waves are observed in approximately one-third of patients with eosinophilic myocarditis. Atrioventricular block, which occurs in viral myocarditis and idiopathic myocarditis, only rarely occurs in eosinophilic myocarditis.

<sup>c)</sup> Left ventricular wall thickening frequently occurs in eosinophilic myocarditis. Its severity varies among patients. Since wall thickening normalizes within 7 to 14 days, the patient must be monitored over time. ECG, electrocardiography.

## 2 Diagnosis

Multinucleated giant cells can be recognized in inflammatory lesions in the myocardium. Differentiation from cardiac sarcoidosis is of crucial importance.<sup>26</sup>

## 3 Treatment

Although there are reports suggesting that corticosteroids and immunosuppressant may be useful for treatment of giant cell myocarditis, the prognosis of giant cell myocarditis is not favorable.<sup>27</sup>

## 3. Eosinophilic Myocarditis

### 1 Background

Eosinophilic myocarditis is caused by cytotoxic substances such as eosinophilic cationic protein contained in the granules of eosinophils, which infiltrate into the myocardium. Its etiology varies, and includes allergic conditions, drug hypersensitivity, and parasite infection, though it is usually idiopathic.<sup>28</sup>

### 2 Diagnosis (Table 4)

Eosinophilic myocarditis is diagnosed based on increased eosinophil counts in peripheral blood and significantly increased eosinophil infiltrates, as well as degranulation and degeneration of cardiomyocytes on biopsy. The timing of the onset of increased eosinophil counts in peripheral blood differs among patients.<sup>29</sup>

### 3 Treatment

Patients with mild eosinophilic myocarditis recover naturally. If the patient has heart failure or serious arrhythmia, corticosteroid treatment is necessary.<sup>30</sup> To prevent cardiac wall thrombi, anticoagulants are used. The prognosis is favorable.

## 4. Chronic Myocarditis

### 1 Background

The concept of chronic myocarditis has not been agreed upon between in Japan and outside of Japan.<sup>3</sup> There are reports suggesting the involvement of viral infection or autoimmunity in chronic myocarditis, though the cause of this condition has not been clearly determined.

### 2 Diagnosis

The diagnosis of chronic myocarditis is difficult. It begins in a latent fashion, but then becomes chronic.<sup>3</sup> Acute myocarditis rarely becomes chronic. The symptoms and signs of chronic myocarditis are non-specific and similar to those of dilated cardiomyopathy. Histological findings are characterized by mononuclear cell infiltrates, aggregated interstitial fibrosis, and fatty infiltration. <sup>67</sup>Ga or <sup>99m</sup>Tc pyrophosphate myocardial scintigraphy and CMR imaging may yield findings suggestive of chronic myocarditis. Blood cardiac troponin level has not been proven to be useful in diagnosis.

### 3 Treatment

Because the etiology of chronic myocarditis is unclear, palliative treatment such as general treatment for heart failure is performed. It has been reported that chronic myocarditis should be treated based on its pathogenesis, such as viral infection or autoimmunity.<sup>31</sup> However, the effectiveness of immunosuppressant has not been confirmed.

## 5. Pediatric Myocarditis

### 1 Background

Pediatric patients with myocarditis include 30 to 40% with the fulminant type and 40 to 50% with the acute type. Chronic myocarditis is rare in pediatric patients. Among pediatric patients, many have viral infections of types seen in daily life. However, adenovirus and enterovirus infections are common causes of pediatric myocarditis.<sup>32</sup> The prognosis of myocarditis in pediatric patients is similar to that in adult patients. The prognosis of fulminant myocarditis is particularly unfavorable in pediatric patients.<sup>33</sup>

### 2 Diagnosis

The typical manifestation of pediatric myocarditis is elevated blood cardiac troponin. Virus can be detected in feces, urine, blood, and sputum. The findings on ECG and echocardiography in pediatric myocarditis are similar to those in adult myocarditis. Echocardiography is the most useful diagnostic tool for pediatric patients.<sup>34</sup> It must be repeated over time, since the disease may progress rapidly over a few hours in pediatric patients. Nuclear medicine techniques with <sup>67</sup>Ga or <sup>99m</sup>Tc pyrophosphate and CMR may be helpful in diagnosis. An endomyocardial biopsy is relatively safe for older children.

### 3 Treatment

Once myocarditis is suspected, the patient must be transferred to a facility capable of performing pediatric emergency treatment. The primary goal of treatment is to maintain hemodynamics. Respiratory care and cardiopulmonary circulatory support must be concurrently administered. Treatment with antiviral agents or high dose immunoglobulin should be pathogen-specific.<sup>35</sup>

## 6. Neonatal Myocarditis

### 1 Background

Mothers of neonates with myocarditis often have signs of infection a few days prior to delivery, and affected neonates have signs of heart failure before birth.<sup>36</sup> The risk of horizontal vertical infection from the mother to the neonate is high. Two-thirds of neonates with myocarditis have fulminant-type disease, and the mortality rate is high, at 50% or more.<sup>37</sup> Coxsackie B virus infection, which causes fatal myocarditis, accounts for approximately 75% of cases of neonatal myocarditis.<sup>38</sup>

### 2 Diagnosis

Myocarditis occurs in neonates at birth. Initially, patients are presented with cardiopulmonary signs and symptoms without fever. The signs and symptoms may be non-specific, such as not doing well, feeding difficulty, vomiting, dyspnea, and seizures. Detection of elevated cardiac troponin level is useful for diagnosis. Viruses are isolated in approximately 50% of patients.

### 3 Treatment

Basically, systemic care and monitoring of the patient is important. Patients must be isolated to prevent spread of infection. Neonates with myocarditis must be immediately transferred to a facility with a neonatal intensive care unit (NICU) or pediatric ICU.

### III Diseases Similar to Myocarditis

#### 1. Cardiac Sarcoidosis

##### 1 Background

Cardiac sarcoidosis is a systemic granulomatous disease of unknown etiology. The prognosis is closely related to the severity of cardiac manifestations. Attention has been given to *Propionibacterium acnes* as a cause, since this organism is isolated from tissue affected by sarcoidosis.

##### 2 Diagnosis

According to the guidelines for cardiac sarcoidosis revised in 2006 (Table 5),<sup>39</sup> a myocardial abnormality of unknown cause is occasionally diagnosed as cardiac sarcoidosis after endo-

myocardial biopsy. If cardiac sarcoidosis is suspected, multi-disciplinary collaboration is required for systemic screening for sarcoidosis.

##### 3 Treatment<sup>40</sup>

Corticosteroid treatment is performed for patients with cardiac sarcoidosis, regardless of the severity of cardiac dysfunction. In general, treatment starts at 30 mg/day of prednisolone, and is continued at 5 to 10 mg/day. If arrhythmia or heart failure occurs, the patient should be given standard treatment. Use of a pacemaker, implantable cardioverter defibrillator, drug treatment for heart failure, and cardiac resynchronization therapy should also be considered.

**Table 5. Diagnostic Guidelines for Cardiac Manifestations of Cardiac Sarcoidosis (2006)**

##### (1) Patient group diagnosed based on histological findings

Histopathological findings include non-necrotizing epithelioid granuloma in the myocardium, and the patient is found to exhibit histopathological changes in organs other than the heart or by clinical signs.

##### (2) Patient group diagnosed based on clinical signs

Histopathological findings do not include non-necrotizing epithelioid granuloma in the myocardium. Patients are diagnosed with cardiac sarcoidosis when they have histopathological changes in organs other than the heart or by clinical signs, together with the following conditions and one or more of six primary diagnostic criteria.

1. Two or more major criteria
2. One major and two or more minor criteria
  - 1) Major criteria
    - (a) Severe atrioventricular block
    - (b) Ventricular septal thinning localized at the basal portion
    - (c) Abnormal uptake of <sup>67</sup>Ga in the heart on <sup>67</sup>Ga scintigraphy
    - (d) Left ventricular contraction failure (left ventricular ejection fraction less than 50%)
  - 2) Minor criteria
    - (a) Abnormal ECG: Ventricular arrhythmia (ventricular tachycardia, multi-origin or frequent ventricular premature beats), right bundle branch block, axis deviation, or abnormal Q waves
    - (b) Echocardiography: Localized abnormal left ventricular wall motion, or morphological abnormalities (ventricular aneurysm and/or ventricular wall thickening)
    - (c) Nuclear medicine techniques: Abnormal blood flow on myocardial perfusion scintigraphy (thallium-201 chloride or technetium-99m methoxyisobutylisonitrile, technetium-99m tetrofosmin)
    - (d) Abnormal imaging on delayed gadolinium-enhanced cardiac MRI
    - (e) Endomyocardial biopsy: Moderate or more severe myocardial interstitial fibrosis and mononuclear cell infiltrates

##### Primary diagnostic criteria in tests:

1. Bilateral hilar lymphadenopathy
2. Elevated serum angiotensin converting enzyme
3. Negative tuberculin reaction
4. Abnormal uptake of <sup>67</sup>Ga in any organ on scintigraphy
5. An increased lymphocyte count and elevated CD4/CD8 ratio in bronchoalveolar lavage fluid
6. Elevated serum or urinary calcium level

##### Diagnostic exclusion: Giant cell myocarditis must be excluded.

##### Additional information:

1. Perform coronary angiography to differentiate from ischemic heart diseases.
2. Cardiac manifestations of sarcoidosis occasionally appear a few years after sarcoidosis in organs other than the heart, have been diagnosed. The patient must therefore be followed with ECG and echocardiography on a regular basis.
3. Abnormal uptake of fluorine-18 fluorodeoxyglucose PET in the heart is a useful diagnostic clue in cardiac sarcoidosis.
4. Some cases of cardiac sarcoidosis are manifested only by complete atrioventricular block without any other minor criteria as listed.
5. Cardiac sarcoidosis may initially manifest itself as pericarditis (as shown by ST segment elevation or pericardial effusion in the ECG).
6. Cases of non-necrotizing epithelioid granuloma are not observed frequently on the endomyocardial biopsy.

<sup>67</sup>Ga, gallium-67; MRI, magnetic resonance imaging; ECG, electrocardiography; PET, positron emission tomography. Adapted from *The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders* 2007; 27: 89–102.



## 2. Autoimmune Myocarditis (Myocarditis Derived From Collagen Diseases)

### 1 Background

Initial manifestations of autoimmune myocarditis include dysfunction of the kidneys, skin, choroid plexus, and inflammation not involving infection such as deposition of immune complexes and activation of complement.

### 2 Diagnosis

Initially, autoimmune myocarditis rarely occurs with myocarditis alone. Pericarditis is associated with the severity of disease activity. A presence of antinuclear antibodies in pericardial effusion, autoantibodies, reduced complement activity, and elevated immune complex levels are supportive of the diagnosis. Echocardiography, myocardial scintigraphy and CMR imaging are used for diagnosis, but an ordinary endomyocardial biopsy is not diagnostic. Scleroderma, systemic lupus erythematosus, polymyositis, dermatomyositis, rheumatoid arthritis, polyarteritis nodosa, and allergic granulomatous angiitis (Churg-Strauss syndrome) are associated with cardiac manifestations.<sup>41</sup>

### 3 Treatment

Autoimmune myocarditis is treated with corticosteroids or concurrent use of immunosuppressant if the patient has decreased cardiac function, severe pericardial effusion, or concurrent dysfunction of other organs.

## 3. Drug-Induced Myocarditis

### 1 Background

This type of myocarditis is induced by drug treatment. Myocarditis may occur in any patient treated with drugs, and must be carefully monitored. Hypersensitivity myocarditis occurs a few days to a few months after exposure to a drug regardless of the dosage used.<sup>42</sup> The severity of toxic myocarditis depends on the dosage and method of administration and drug metabolism in patients, and the onset of this type of myocarditis is slow.

### 2 Diagnosis

An endomyocardial biopsy is of crucial importance to the diagnosis of drug-induced myocarditis. However, diagnosis also requires information such as history of drug treatment and clinical conditions after discontinuation of the suspected drug, since differentiation of drug-induced myocarditis from acute myocarditis of other etiologies is difficult. Blood cardiac troponin is useful for diagnosis. Although hypersensitivity myocarditis presents with an elevated eosinophil count, the usefulness of the eosinophil count in diagnosis is unclear.

### 3 Treatment

Discontinuation of the suspected drug is the most effective method of treatment. Treatment with corticosteroids is also expected to be useful for hypersensitivity myocarditis and drug-induced hypersensitivity syndrome.<sup>43</sup> After the patient recovery, re-administration of the suspected drug must be prevented.

## IV Conclusion

The diagnosis of myocarditis is difficult. The first step in diagnosis is to suspect myocarditis. The primary principles of treatment are to make the clinical diagnosis and manage cardiopulmonary emergency promptly. Every effort must be

made to confirm the diagnosis of myocarditis by histology, since some cases of specific myocarditis may respond to corticosteroid treatment.

### References

- Clements GB. Characteristics of viruses inducing cardiac disease. *In*: Banatvala JE, editor. *Viral infections of the heart*. London: Edward Arnold, 1993; 1–22.
- Bowles NE, Ni J, Kearney DL, Pauschinger M, Schultheiss HP, McCarthy R, et al. Detection of viruses in myocardial tissues by polymerase chain reaction: Evidence of adenovirus as a common cause of myocarditis in children and adults. *J Am Coll Cardiol* 2003; **42**: 466–472.
- Japanese Circulation Society (JCS) Task Force Committee on Chronic Myocarditis. Guideline for diagnosing chronic myocarditis. *Jpn Circ J* 1996; **60**: 263–264.
- Aoyama N, Izumi T, Hiramori K, Isobe M, Kawana M, Hiroe M, et al. Japanese Investigators of Fulminant Myocarditis: National survey of fulminant myocarditis in Japan: Therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee). *Circ J* 2002; **66**: 133–144.
- Kawamura K, Kitaura Y, Deguchi H, Kodaka M. The Etiology Unit of the MHW Specific Disease Idiopathic Cardiomyopathy Study Group: Nationwide questionnaire survey on viral or idiopathic cardiomyopathy, third report—Results of survey in 1982 and 1985. *In*: MHW Specific Disease Idiopathic Cardiomyopathy Study Group Report in 1985. 1986; 23–36 (in Japanese).
- Lauer B, Niederau C, Kühl U, Schannwell M, Pauschinger M, Strauer BE, et al. Cardiac troponin T in patients with clinically suspected myocarditis. *J Am Coll Cardiol* 1997; **30**: 1354–1359.
- Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. *Circulation* 1997; **95**: 163–168.
- Hiramitsu S, Morimoto S, Kato S, Uemura A, Kubo N, Kimura K, et al. Transient ventricular wall thickening in acute myocarditis: A serial echocardiographic and histological study. *Jpn Circ J* 2001; **65**: 863–866.
- Liu PP, Yan AT. Cardiovascular magnetic resonance for the diagnosis of acute myocarditis: Prospects for detecting myocardial inflammation. *J Am Coll Cardiol* 2005; **45**: 1823–1825.
- Abdel-Aty H, Boyé P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: Comparison of different approaches. *J Am Coll Cardiol* 2005; **45**: 1815–1822.
- Laissy JP, Hyafil F, Feldman LJ, Juliard JM, Schouman-Claeys E, Steg PG, et al. Differentiating acute myocardial infarction from myocarditis: Diagnostic value of early- and delayed perfusion cardiac MR imaging. *Radiology* 2005; **237**: 75–82.
- O'Connell JB, Henkin RE, Robinson JA, Subramanian R, Scanlon PJ, Gunnar RM. Gallium-67 imaging in patients with dilated cardiomyopathy and biopsy-proven myocarditis. *Circulation* 1984; **70**: 58–62.
- Morguet AJ, Munz DL, Kreuzer H, Emrich D. Scintigraphic detection of inflammatory heart disease. *Eur J Nucl Med* 1994; **21**: 666–674.
- Kawai C. From myocarditis to cardiomyopathy: Mechanisms of inflammation and cell death: Learning from the past for the future. *Circulation* 1999; **99**: 1091–1100.
- Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure

- Society of America and the Heart Failure Association of the European Society of Cardiology. *J Am Coll Cardiol* 2007; **50**: 1914–1931.
16. Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. *Circulation* 2005; **111**: 887–893.
  17. Kawamura K, Kitaura Y, Deguchi H. The Etiology Unit of the MHW Specific Disease Idiopathic Cardiomyopathy Study Group: Guidelines for the diagnosis of acute cardiomyopathy. In: MHW Specific Disease Idiopathic Cardiomyopathy Study Group Report in 1986. 1987; 13–14 (in Japanese).
  18. Okada R, Sekiguchi M, Kawamura K, Kawai C, Toshima H, Nimura Y. Criteria for pathological diagnosis of viral or idiopathic cardiomyopathy with myocardial biopsy: Pathology unit collaborative study. In: MHW Specific Disease Idiopathic Cardiomyopathy Study Group Report in 1988. 1989; 181–182 (in Japanese).
  19. Kodama M, Okura Y, Hirano S, Hanawa H, Ogawa Y, Itoh M, et al. A new scoring system to predict the efficacy of steroid therapy for patients with active myocarditis: A retrospective study. *Jpn Circ J* 1998; **62**: 715–720.
  20. McNamara DM, Rosenblum WD, Janosko KM, Trost MK, Villaneuva FS, Demetris AJ, et al. Intravenous immunoglobulin in the therapy of myocarditis and acute cardiomyopathy. *Circulation* 1997; **95**: 2476–2478.
  21. Kodama M, Oda H, Okabe M, Aizawa Y, Izumi T. Early and long-term mortality of the clinical subtypes of myocarditis. *Jpn Circ J* 2001; **65**: 961–964.
  22. Chen YS, Yu HY, Huang SC, Chiu KM, Lin TY, Lai LP, et al. Experience and result of extracorporeal membrane oxygenation in treating fulminant myocarditis with shock: What mechanical support should be considered first? *J Heart Lung Transplant* 2005; **24**: 81–87.
  23. Kato S, Morimoto S, Hiramitsu S, Uemura A, Ohtsuki M, Kato Y, et al. Risk factors for patients developing a fulminant course with acute myocarditis. *Circ J* 2004; **68**: 734–739.
  24. McCarthy RE 3rd, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. *N Engl J Med* 2000; **342**: 690–695.
  25. Shirani J, Freant LJ, Roberts WC. Gross and semiquantitative histologic findings in mononuclear cell myocarditis causing sudden death, and implications for endomyocardial biopsy. *Am J Cardiol* 1993; **72**: 952–957.
  26. Okura Y, Dec WG, Hare JM, Kodama M, Berry GJ, Tazelaar HD, et al. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. *J Am Coll Cardiol* 2003; **41**: 322–329.
  27. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis. natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. *N Engl J Med* 1997; **336**: 1860–1866.
  28. Mori N, Morimoto S, Hiramitsu S, Uemura A, Kubo N, Ohtsuki M, et al. Clinical pictures of 35 cases with eosinophilic myocarditis. *Circ J* 2004; **68**(Suppl 1): 244 (abstract).
  29. Morimoto S, Kubo N, Hiramitsu S, Uemura A, Ohtsuki M, Kato S, et al. Changes in the peripheral eosinophil count in patients with acute eosinophilic myocarditis. *Heart Vessels* 2003; **18**: 193–196.
  30. Watanabe N, Nakagawa S, Fukunaga T, Fukuoka S, Hatakeyama K, Hayashi T. Acute necrotizing eosinophilic myocarditis successfully treated by high dose methylprednisolone. *Jpn Circ J* 2001; **65**: 923–926.
  31. Burgstaler EA, Cooper LT, Winters JL. Treatment of chronic dilated cardiomyopathy with immunoadsorption using the staphylococcal A-agarose column: A comparison of immunoglobulin reduction using two different techniques. *J Clin Apher* 2007; **22**: 224–232.
  32. Wistø E, Palacios G, Cinek O, Stene LC, Grinde B, Janowitz D, et al. High prevalence of human enterovirus A infections in natural circulation of human enteroviruses. *J Clin Microbiol* 2006; **44**: 4095–4100.
  33. Guarner J, Paddock CD, Shien WJ, Packard MM, Patel M, Montague JL, et al. Histopathologic and immunohistochemical features of fatal influenza virus infection in children during the 2003–2004 season. *Clin Infect Dis* 2006; **43**: 132–140.
  34. Nieminen MS, Heikkilä J, Karjalainen J. Echocardiography in acute infectious myocarditis: Relation to clinical and electrocardiographic findings. *Am J Cardiol* 1984; **53**: 1331–1337.
  35. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2002–2003 Joint Working Groups Report). Guidelines for Diagnosis and Treatment of Myocarditis. *Circ J* 2004; **68**(Suppl IV): 1231–1263 (in Japanese).
  36. Bendig JW, Franklin OM, Hebden AK, Backhouse PJ, Clewley JP, Goldman AP, et al. Coxsackievirus B3 sequences in the blood of a neonate with congenital myocarditis, plus serological evidence of maternal infection. *J Med Virol* 2003; **70**: 606–609.
  37. Saji T, Nakazawa M, Harada K, Matsuura H. Diagnosis and treatment of acute myocarditis in neonatal period: Nationwide surveillance. *Pediatric Cardiology and Cardiac Surgery* 2004; **20**: 12–15 (in Japanese).
  38. Abzug MJ. Perinatal enterovirus infections. In: Rotbart HA, editor. Human enterovirus infections. Washington DC: ASM Press; 1995: 221–238.
  39. Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. *J Am Coll Cardiol* 2005; **45**: 1683–1690.
  40. The Japan Society of Sarcoidosis and other Granulomatous Disorders, the Japanese Respiratory Society, the Japanese College of Cardiology, the Japanese Ophthalmological Society, the MHLW Science Research–Diffuse Pulmonary Disease Study Group of the Specific Disease Treatment Program, editors. Outline of the treatment of sarcoidosis in 2003. Available at <http://jssog.com/> (accessed in March 2009) (in Japanese).
  41. Tamura N. Pericarditis in collagen disease and systemic vasculitis. In: Yazaki Y, editor. Cardiovascular syndromes II. Osaka: Nippon Rinsho Sha; 2007; 368–371 (in Japanese).
  42. Hashimoto K. Study of criteria for diagnosis and guidelines for treatment of Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), and hypersensitivity syndrome. In: MHLW Science Special Research Program Final Report (2005) (In Japanese).
  43. The Ministry of Health, Labour and Welfare. Treatment manual for serious adverse drug reactions–Drug sensitivity syndrome. June 2007 (In Japanese).

#### Appendix

##### Chair:

- Tohru Izumi, Department of Cardio-angiology, Kitasato University, School of Medicine

##### Members:

- Michiaki Hiroe, Division of Nephrology & Cardiology, National Center for Global Health and Medicine
- Mitsuaki Isobe, Department of Cardiovascular Medicine, Tokyo Medical and Dental University
- Sachio Kawai, Division of Cardiology, Department of Internal Medicine, Juntendo University School of Medicine
- Masatoshi Kawana, Department of Cardiology, Tokyo Women’s Medical University, Aoyama Hospital
- Kazuo Kimura, Division of Cardiology, Yokohama City University Medical Center
- Makoto Kodama, Division of Cardiology, Department of Cardiovascular and Vital Control, Graduate School of Medical and Dental Sciences, Niigata University
- Shunei Kyo, Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo
- Akira Matsumori, Department of Cardiology, Tokyo Medical University
- Masunori Matsuzaki, Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine
- Shin-ichiro Morimoto, Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine
- Tsutomu Saji, Department of Pediatrics, Toho University Medical Center, Omori Hospital
- Chikao Yutani, Department of Life Science, Okayama University of Science

##### Collaborators:

- Kyoko Imanaka-Yoshida, Department of Pathology and Matrix Biology, Mie University Graduate School of Medicine
- Takayuki Inomata, Department of Cardio-angiology, Kitasato University, School of Medicine
- Hatsue Ishibashi-Ueda, Department of Pathology, National Cerebral and Cardiovascular Center
- Masahiro Ishii, Department of Pediatrics, Kitasato University, School of Medicine
- Hiroshi Nakamura, Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine

- Kazufumi Nakamura, Department of Cardiovascular Medicine, Okayama University
  - Toshio Nishikawa, Department of Surgical Pathology, Tokyo Women's Medical University
  - Ryosuke Nishio, Division of Emergency Medicine, Kyoto University Hospital
  - Shinichi Nunoda, Department of Medicine, Tokyo Women's Medical University Medical Center East
  - Hiroshi Okamoto, Division of Cardiovascular Medicine, Nishi Sapporo National Hospital
  - Yuji Okura, Department of Internal Medicine, Niigata Cancer Center Hospital
  - Mamoru Satoh, Division of Cardiology and Memorial Heart Center, Department of Internal Medicine, Iwate Medical University School of Medicine
  - Tetsuo Shioi, Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University
  - Hiroyuki Takano, Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
  - Fumio Terasaki, Department of Internal Medicine III, Osaka Medical College
  - Yoshikazu Yazaki, Division of Cardiovascular Medicine, Matsumoto Medical Center, Matsumoto Hospital
  - Tsutomu Yoshikawa, Division of Cardiology, Department of Medicine, Keio University School of Medicine
- Independent Assessment Committee:
- Masahiko Kurabayashi, Department of Medicine and Biological Science, Gunma University Graduate School of Medicine
  - Ken Okumura, Department of Cardiology Respiratory Medicine and Nephrology, Hirosaki University Graduate School of Medicine
  - Hitonobu Tomoike, National Cerebral and Cardiovascular Center
  - Akira Yamashina, Second Department of Internal Medicine, Tokyo Medical University
  - Michihiro Yoshimura, Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine
- (The affiliations of the members are as of September 2010)

## Persistence of pandemic influenza H1N1 virus in young patients after oseltamivir therapy in the 2009–2010 season: a comparison with seasonal H1N1 with or without H275Y mutation

Naoki Kawai · Hideyuki Ikematsu · Norio Iwaki · Kunio Kondou · Nobuo Hirotsu · Takashi Kawashima · Tetsunari Maeda · Osame Tanaka · Ken-ichi Doniwa · Osamu Iwakuni · Keisuke Egashira · Kouzaburo Yamaji · Seizaburo Kashiwagi

Received: 17 May 2011 / Accepted: 20 September 2011 / Published online: 23 December 2011  
© Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2012

**Abstract** Comparison of the viral persistence of pandemic H1N1 (H1N1pdm) and seasonal H1N1 with or without H275Y mutation after oseltamivir therapy has not been adequately done. Virus was isolated before and on days 4–6 from the start of oseltamivir treatment for 158 cases of seasonal (2007–2008 and 2008–2009 seasons) or pandemic (2009–2010 season) H1N1 influenza. Sequence analysis was done for each season and NA inhibition assay (IC<sub>50</sub>) was done in the 2009–2010 season. H275Y mutation before therapy was 0% in the 2007–2008 and 2009–2010 seasons, but 100% in the 2008–2009 season. Fever and other symptoms were noticeably prolonged after oseltamivir therapy for children with H275Y mutated seasonal H1N1 (2008–2009 season), but not in patients with seasonal H1N1 without mutation (2007–2008) or H1N1pdm (2009–2010). The viral persistence rate was significantly higher for patients 15 years or younger than for those 16 years and older with H275Y mutated seasonal H1N1 (46.2% and 10.5%, respectively) or with H1N1pdm (43.3% and 11.5%, respectively). The H275Y mutation emerged

after oseltamivir treatment in 2.4% (2/82) of all patients with H1N1pdm. In two children, the H275Y mutation emerged after therapy and the IC<sub>50</sub> increased more than 200 fold; however, the prolongation of fever was not so prominent. In conclusion, oseltamivir was effective for fever and other clinical symptoms; however, the virus persisted longer than expected after treatment in H1N1pdm influenza-infected children in the 2009–2010 season, similar to seasonal H1N1 with H275Y mutation in the 2008–2009 season.

**Keywords** Influenza A(H1N1) · Oseltamivir · Viral shedding · H275Y mutation · IC<sub>50</sub>

### Introduction

The prodrug oseltamivir phosphate (oseltamivir), an oral neuraminidase (NA) inhibitor, had been effective against seasonal influenza A infection until the 2007–2008 season [1–7], but became less effective in the 2008–2009 season, when seasonal H1N1 influenza with the H275Y mutation [8, 9] was widespread throughout Japan [10, 11]. The reduction was more prominent in children than in adults [10, 11], however, oseltamivir was effective for the pandemic H1N1 (H1N1pdm) influenza that emerged in 2009, as shown by our previous study estimating the duration of fever after the start of oseltamivir therapy [12].

There is great concern about the length of the viral shedding period after oseltamivir therapy for H1N1pdm infection, because longer viral shedding holds the possibility of inducing secondary infection in the home or community. A longer viral shedding period may also be related to the emergence of viral mutation of H1N1pdm viruses [7, 10, 13]. Although the frequency of H275Y mutation of

N. Kawai and H. Ikematsu contributed equally to this work.

N. Kawai · H. Ikematsu · N. Iwaki · K. Kondou · N. Hirotsu · T. Kawashima · T. Maeda · O. Tanaka · K. Doniwa · O. Iwakuni · K. Egashira · K. Yamaji · S. Kashiwagi  
Japan Physicians Association, Tokyo Medical Association  
Building 3F, 2-5 Kanda-Surugadai, Chiyoda-ku,  
Tokyo 101-0062, Japan

N. Kawai (✉) · H. Ikematsu  
4-9 Tonomachi, Gifu, Gifu 500-8116, Japan  
e-mail: nkawai@city.gifu.med.or.jp

H. Ikematsu  
Department of Clinical Trials, Center for Advanced Medical  
Innovation, Kyushu University, Fukuoka, Japan